HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Protective effects of ischemic preconditioning and application of lipoic acid prior to 90 min of hepatic ischemia in a rat model.

AbstractAIM:
To compare different preconditioning strategies to protect the liver from ischemia/reperfusion injury focusing on the expression of pro- and anti-apoptotic proteins. Interventions comprised different modes of ischemic preconditioning (IP) as well as pharmacologic pretreatment by alpha-lipoic acid (LA).
METHODS:
Several groups of rats were compared: sham operated animals, non-pretreated animals (nt), animals receiving IP (10 min of ischemia by clamping of the portal triad and 10 min of reperfusion) prior to sustained ischemia, animals receiving selective ischemic preconditioning (IPsel, 10 min of ischemia by selective clamping of the ischemic lobe and 10 min of reperfusion) prior to sustained ischemia, and animals receiving 500 micromol alpha-LA injected i.v. 15 min prior to the induction of 90 min of selective ischemia.
RESULTS:
Cellular damage was decreased only in the LA group. TUNEL-positive hepatocytes as well as necrotic hepatocyte injury were also decreased only by LA (19 +/- 2 vs 10 +/- 1, P < 0.05 and 29 +/- 5 vs 12 +/- 1, P < 0.05). Whereas caspase 3- activities in liver tissue were unchanged, caspase 9- activity in liver tissue was decreased only by LA pretreatment (3.1 +/- 0.3 vs 1.8 +/- 0.2, P < 0.05). Survival rate as the endpoint of liver function was increased after IP and LA pretreatment but not after IPsel. Levels of lipid peroxidation (LPO) in liver tissue were decreased in the IP as well as in the LA group compared to the nt group. Determination of pro- and anti-apoptotic proteins showed a shift towards anti-apoptotic proteins by LA. In contrast, both our IP strategies failed to influence apoptotic cell death.
CONCLUSION:
IP, consisting of 10 min of ischemia and 10 min of reperfusion, protects only partly against ischemia/reperfusion injury of the liver prior to 90 min of selective ischemia. IPsel did not influence ischemic tolerance of the liver. LA improved tolerance to ischemia, possibly by downregulation of pro-apoptotic Bax.
AuthorsFriedrich Duenschede, Kirsten Erbes, Nina Riegler, Patrick Ewald, Achim Kircher, Stefanie Westermann, Arno Schad, Imke Miesmer, Simon Albrecht-Schöck, Ines Gockel, Alexandra K Kiemer, Theodor Junginger
JournalWorld journal of gastroenterology (World J Gastroenterol) Vol. 13 Issue 27 Pg. 3692-8 (Jul 21 2007) ISSN: 1007-9327 [Print] United States
PMID17659728 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Apoptosis Regulatory Proteins
  • Bax protein, rat
  • Isoenzymes
  • Protective Agents
  • Proto-Oncogene Proteins c-bcl-2
  • bcl-2-Associated X Protein
  • Thioctic Acid
  • Glutathione Transferase
  • glutathione S-transferase alpha
  • Casp9 protein, rat
  • Caspase 3
  • Caspase 9
Topics
  • Animals
  • Apoptosis (drug effects)
  • Apoptosis Regulatory Proteins (metabolism)
  • Caspase 3 (metabolism)
  • Caspase 9 (metabolism)
  • Disease Models, Animal
  • Glutathione Transferase (blood)
  • Ischemia (complications, enzymology, metabolism, pathology)
  • Ischemic Preconditioning (methods)
  • Isoenzymes (blood)
  • Lipid Peroxidation (drug effects)
  • Liver (blood supply, drug effects, metabolism, pathology)
  • Male
  • Necrosis
  • Protective Agents (pharmacology, therapeutic use)
  • Proto-Oncogene Proteins c-bcl-2 (metabolism)
  • Rats
  • Rats, Inbred BN
  • Reperfusion Injury (enzymology, etiology, metabolism, pathology, prevention & control)
  • Thioctic Acid (pharmacology, therapeutic use)
  • Time Factors
  • bcl-2-Associated X Protein (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: